Trial Profile
A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms BC-APPS1
- 02 May 2023 Status changed from active, no longer recruiting to completed.
- 30 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2023.
- 30 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Mar 2023.